RxDoctor Payments Data

Cong Yu, MD

Anesthesiology · Seattle, WANPI 1457398158

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (45.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Nevro Corp. at 40.2% of the total. Reporting peaked in 2021 at $14,836 and has fallen 72.8% since, to $4,042 in 2025. Among anesthesiology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$56,375in general payments, 2019–2025

Across 376 payments — averaging $149.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$23K
  • Boston Scientific$20K
  • Medtronic$5K
  • Saluda Medical Americas, Inc.$2K
  • Si-bone, Inc.$1K
  • Abbott$893
  • plus $4K from 17 others
$658,228in research payments, 2019–2025

Across 126 payments — averaging $5224.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Nevro Corp.$543K
  • Globus Medical$55K
  • Boston Scientific$34K
  • Seikagaku Corporation$26K

What the payments were for

  • Consulting fees$16,04428%
  • Speaking & faculty fees$6,18511%
  • Travel & lodging$8,65715%
  • Food & beverage$25,49045%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,375 in reported general payments places this provider in the 95th percentile of 1,206 anesthesiology providers in Washington.

See all anesthesiology providers in Washington

Medicare billing

Part B allowed, 2024
$101,686
Medicare patients
252
Services billed
975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl28$9,974
Buprenorphine45$7,385
Fentanyl60$7,362
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl23$3,558
Morphine Sulfate ErMorphine Sulfate86$3,353
Oxycodone Hcl169$2,867
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen93$2,280
Pregabalin86$2,221
Gabapentin100$1,244
Tizanidine Hcl67$1,199
Baclofen46$1,115
Methadone Hcl20$631
Buprenorphine Hcl27$580
Duloxetine Hcl32$527
Hydromorphone Hcl25$436

Paid to pharmacies, not to this prescriber.

Other anesthesiology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →